Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Monte Rosa Therapeutics (Nasdaq: GLUE) announced that CEO Markus Warmuth, M.D. will participate in fireside chats at four investor conferences in November–December 2025.
Scheduled participations: Guggenheim Healthcare Innovation (Boston) on Nov 10, 2025 at 11:30 a.m. ET; TD Cowen Immunology & Inflammation Summit (virtual) on Nov 13, 2025 at 12:00 p.m. ET; Jefferies Global Healthcare (London) on Nov 18, 2025 at 11:30 a.m. GMT; and Piper Sandler Healthcare (New York) on Dec 2, 2025 at 1:30 p.m. ET.
Webcasts will be available via the company’s Events & Presentations page at ir.monterosatx.com and archived for 30 days after each presentation.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, GLUE declined 6.07%, reflecting a notable negative market reaction. Argus tracked a trough of -11.5% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $51M from the company's valuation, bringing the market cap to $794M at that time.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in fireside chats at the following investor conferences:
- Guggenheim 2nd Annual Healthcare Innovation Conference (Boston, MA) – November 10, 2025, at 11:30 a.m. ET
- TD Cowen Immunology & Inflammation Summit (virtual) – November 13, 2025, at 12:00 p.m. ET
- Jefferies Global Healthcare Conference in London – November 18, 2025, at 11:30 a.m. GMT
- Piper Sandler 37th Annual Healthcare Conference (New York, NY) – December 2, 2025, at 1:30 p.m. ET
Webcasts of the fireside chats will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and archived versions will be made available for 30 days following the presentations.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
FAQ
When will Monte Rosa Therapeutics (GLUE) present at the Guggenheim Healthcare Innovation Conference?
How can investors watch Monte Rosa Therapeutics (GLUE) at the TD Cowen Immunology & Inflammation Summit on November 13, 2025?
What time is Monte Rosa Therapeutics (GLUE) scheduled to speak at Jefferies Global Healthcare Conference in London?
Will Monte Rosa Therapeutics (GLUE) provide webcasts of the Piper Sandler conference presentation on December 2, 2025?
Where can archived webcasts of Monte Rosa Therapeutics (GLUE) investor presentations be found and for how long?
